Last edition
News about "pembrolizumab "
EU Approves KEYTRUDA for PD-L1+ Resectable Head and Neck Cancer
KEYTRUDA monotherapy has been approved for use as a neoadjuvant treatment, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and continued thereafter as maintenance monotherapy.
Pembrolizumab | 30/10/2025 | By Dineshwori
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
Pembrolizumab | 11/10/2025 | By Dineshwori | 447
BerGenBio Begins Phase 2a in First Line NSCLC Patients with STK11m
BerGenBio ASA has initiated Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non-Small Cell Lung Cancer (NSCLC) patients
Pembrolizumab | 21/03/2024 | By Manvi | 519
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy